Status:
RECRUITING
Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients
Lead Sponsor:
Yun Dai Chen
Collaborating Sponsors:
Sanofi
Conditions:
Acute Coronary Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this study is to investigate the effectiveness of in-hospital initiation of alirocumab combined with statin ± ezetimibe on major cardiovascular events (MACE) in Chinese ACS patients. ...
Eligibility Criteria
Inclusion
- Patients diagnosed with Acute Coronary Syndrome (ACS) upon hospital admission.
- Patients aged 18 years or older.
- Patients who received Alirocumab 75 mg in combination with statin therapy ± Ezetimibe as the intervention group, and those treated exclusively with statin therapy ± Ezetimibe as the control group, either during hospitalization or at discharge.
- Patients with at least one follow-up record.
Exclusion
- Patients who received Evolocumab treatment at any time.
- Patients who received Inclisiran treatment at any time.
Key Trial Info
Start Date :
August 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2025
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT06567418
Start Date
August 1 2024
End Date
January 31 2025
Last Update
August 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100853